Canadian Cannabis Industry is Valued Less than Biotech GW Pharma

Canadian cannabis stocks Q4-15

Alan Brochstein published an article on the publicly-traded Canadian cannabis stocks, including Aphria, Aurora Cannabis, Canopy Growth, Emerald Health, Mettrum, OrganiGram, PharmaCan Capital and Supreme Pharma. The article, which is the first in a series, included background on both the MMPR program and the potential legalization in Canada, a discussion of the 8 companies and a comparison of the valuation of the industry relative to GW Pharma, which has binary risk of drug approval and may not generate the level of sales that the Canadian LPs could produce in the coming years.

Summary

  • Canada has become the global leader in the legal cannabis industry.
  • There are several publicly-traded companies holding licenses and exhibiting strong growth.
  • The entire sector is valued less than biotech GW Pharma.
  • 2016 could see Canada become the first G-7 country to legalize cannabis for adult use.

Read Alan Brochstein’s “Capitalizing On Cannabis In Canada – Part 1”: http://seekingalpha.com/article/3778636-capitalizing-on-cannabis-in-canada-part-1

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter